Business, energy, technology, markets and global industry news from Business News Today

Angelini Pharma

PharmaDeviceNews Angelini Pharma
Representative image: Angelini Pharma’s $4.1 billion Catalyst Pharmaceuticals acquisition highlights the growing race for rare disease and neurology assets, with Firdapse, Agamree and U.S. commercial scale at the center of the deal.
Pharma & Biotech

Angelini Pharma bets $4.1bn on rare neurology scale with Catalyst Pharmaceuticals

Angelini gains U.S. rare disease scale. Catalyst gets certainty, but Firdapse concentration keeps the real test ahead.

Read More
Pharma & Biotech

Quiver Bioscience deal shows how Angelini Pharma is rethinking genetic epilepsy innovation

Angelini Pharma partners with Quiver Bioscience to discover new genetic epilepsy targets. Find out what this changes for drug discovery and patients.

Read More